Skip to main content
. 2019 Dec 16;25(6):384–389. doi: 10.4103/sjg.SJG_44_19

Table 2.

Univariate analyses of community-acquired and nosocomial CDI

Community-onset n=55 (84.6%) Nosocomial n=10 (15.4%) P OR (95% CI)
Sex, n (%)
 Female 27 (49.1) 6 (60) 0.73 1.5 (0.4-6.13)
 Male 28 (50.9) 4 (40)
Age groups, n (%)
 18-28 15 (27.3) 1 (10) 0.003*
 29-38 16 (29.1) 0
 39-48 15 (27.3) 1 (10)
 49-58 3 (5.5) 3 (30)
 59-65 3 (5.5) 2 (31)
 >65 3 (5.5) 3 (30)
Presence of IBD, n (%) 41 (74.5) 3 (30) 0.01* 6.8 (1.5-30.08)
Previous antibiotic use,** n (%) 25 (45.5) 9 (90) 0.01* 0.09 (0.01-0.78)
Previous PPI use, n (%) 22 (40) 4 (40) 1 1 (0.25-3.95)
Immunosuppressive therapy, n (%) 29 (52.7) 4 (40) 0.5 1.6 (0.42-6.64)
Malignancy, n (%) 2 (3.6) 2 (31) 0.1 0.15 (0.01-1.22)

OR: Odds ratio; CI: Confidence interval; IBD: Inflammatory bowel disease; PPI: Proton pump inhibitor, *P≤0.05 was considered statistically significant, **Patients who used antibiotics in last 3 months